sa国际传媒官网网页入口Completes Expansion of Singapore Clinical Supply Facility for Increased Temperature-Controlled Capabilities
SOMERSET, N.J. 鈥 February 14, 2023 鈥 Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the completion of a $2.2 million expansion to its clinical supply facility in Singapore, which has seen the site鈥檚 footprint increase to 31,000 square feet creating the space to install an additional 35 new freezers for ultra-low temperature (ULT) storage.
The investment has also increased the facility鈥檚 capabilities to support larger packaging campaigns through the addition of specialized secondary packaging capabilities for ULT products, as well as increasing its ability to handle biopharmaceuticals and advanced modalities, including mRNA-based vaccines, and cell and gene therapies.
鈥淭he Singapore site was the first sa国际传媒官网网页入口clinical supply facility in the Asia-Pacific region, and now serves as a strategic supply hub, shipping clinical materials with high reliability and speed to over 20 countries,鈥 said Tracey Clare, General Manager of APAC Operations for Catalent. 鈥淭his year marks the site鈥檚 25-year anniversary, and through the investments and expansions we have made over that time, it is well positioned to support the needs of modern Asia-Pacific and global clinical trials.鈥
Alongside sites in China and Japan, Catalent鈥檚 site in Singapore serves the Asia-Pacific region with a wide range of clinical supply services including clinical supply management, comparator sourcing, Catalent鈥檚 FastChain庐 demand-led supply solution, secondary packaging, storage, and global distribution, as well as clinical returns and destruction.
NOTES FOR EDITORS
ABOUT CATALENT
sa国际传媒官网网页入口is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, sa国际传媒官网网页入口is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.
sa国际传媒官网网页入口helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent鈥檚 expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.
Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit .